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Summary Factors associated with the failure of intravenous infusions due to phlebitis and extravasation were
studied with 218 infusions delivering cytotoxic drugs. The survival rate of these infusions was not significantly
different from that of 56 non-cytotoxic infusions in oncology patients. Although survival analysis indicated
that cisplatin was associated with longer survival, this was probably an artifact caused by this drug usually
being preceded by 24 h prehydration. Multivariate analysis indicated that etoposide was the only drug
associated with decreased infusion survival and that bleomycin, cyclophosphamide, doxorubicin, ifosphamide,
methotrexate, treosulphan and 5-fluorouracil had no significant effects. Also age of patient, infusion site and
flow rate had no effects but survival was shorter in women. Follow-up indicated that failure of an infusion
tended to result in loss of the vein. It is suggested that irritancy of the large volumes of intravenous fluids
given to hydrate these patients rather than the cytotoxic drugs was the main factor reducing the survival of
these infusions.
Cytotoxic chemotherapy is frequently given by intravenous
infusions. There is a common belief that cytotoxic drugs are
highly irritant to veins and frequently cause phlebitis which
results in the loss of many superficial veins. Consequently
difficult venous access during later stages of treatment is
experienced by some patients. Band and Maki (1980) observ-
ed that phlebitic problems with infusions in leukaemic
patients were 'significantly more frequently associated with
administration of dextrose-containing infusate or intravenous
antibiotics, granulocytopenia, cannulations exceeding 24 h
and local infections'. Most other papers on problems with
cytoxic infusions describe skin loss caused by extravasation
of drugs such as doxorubicin (e.g Rudolph & Larson, 1987;
Cohen, 1979; Lynch et al., 1979; Upton et al., 1979) but there
are a few reports of phlebitis following bolus injections of
concentrated solutions of cytotoxic drugs (Baglin & Bough-
ton, 1986) and isolated comments in several papers to the
effect that particular drugs are 'irritant' or cause phlebitis,
extravasation or vein loss (e.g Long et al., 1987). The only
survey done to identify which cytotoxic drugs are thrombo-
phlebitic (Henney et al., 1977) was small and there is little
information on the incidence ofphlebitis or extravasation with
cytotoxic drugs and none on the loss of veins. This paper
presents the results of a survey of infusions done to identify
factors related to infusion failure in oncology patients.
Methods
The data were collected from 122 oncology patients who
received peripheral infusions with intended durations of at
least 24 h. Infusions were started by three senior house
officers and supervised by specialist oncology nurses. Cannu-
lation was usually with a 18 gauge Venflon cannula which
was normally secured with adhesive plaster and covered with
a loose bandage. Details were recorded for intravenous solu-
tions and drugs given and the infusion site. Sites were
inspected twice each day for signs of phlebitis and extravasa-
tion. Phlebitis was defined as the development of two of the
following: tenderness, erythema, cording and induration
along the infused vein. If phlebitis or extravasation occurred,
infusions were classed as 'failed' even though treatment may
have been completed when the cannula was removed.
Infusion duration was calculated to the nearest hour as the
time interval between the start and cessation of continuous
infusion of fluids. These data were analysed by the univariate
life table method. This generates a 'life table' ('survival
curve') for each factor and significant differences between
factors were identified by the log-rank test (Peto et al., 1977).
The relative rate of failure (RRF) is used to compare differ-
ent treatments for RRF values of less than one and greater
than one indicated decreased and increased failure respec-
tively. The ratio of two RRFs (failure rate ratio) for survival
curves for two treatments then is a measure of the magnitude
of difference between the treatments. As several drugs were
often given in combination, the hypothesis that inclusion of
individual drugs altered infusion survival was tested.
Multivariate analysis was done with Cox's proportional
hazards model using the BioMedical Data Package (BMDP)
with default values and stepwise maximum partial likelihood
ratio (MPLR) selection of variables.
When an infusion site could be located precisely at a
subsequent visit (from notes and the patients memory),
patency of the vein proximal to the infusion site was deter-
mined by inspection and palpation.
Results
Of 284 infusion sites studied, 78 (27.4%) failed with 32
extravasating, 41 becoming phlebitic and five extravasating
with obvious phlebitic signs. Of the failed infusions, 46 (13
for extravasation and 32 for phlebitis) required resiting for
treatment (usually less than 72 h) to continue. In addition,
four, three, one and one infusions were resited because of
'blockage', dislodgement, clotting and leakage respectively
but these were not classed as failed.
Statistics for oncology patients such as age, sex, cannula
site and average fluid rate are shown in Table I. None of
these factors was significant by univariate analysis.
Cytotoxic drugs were infused at 228 sites while the 56
other sites received only crystaloid fluids and sometimes
antibiotics. There was no significant difference between cyto-
toxic and non-cytotoxic infusions (RRFs 1.02 and 0.99
respectively, X2=0.01) (Figure 1).
The most common drug given was cisplatin with bleo-
mycin, etoposide, methotrexate, treosulphan and 5-fluorour-
acil (5-FU) also being used frequently. Other drugs (mitozan,
JM8 and vinblastine) were used only occasionally (three, two
and one times respectively). Univariate analyses of survival
of infusions with individual drugs (Table II) showed that
only cisplatin was associated with a statistically significant
difference (this was longer survival).
Table III shows factors selected by the multifactorial
analysis. Cisplatin was associated with longer survival while
infusions in females and infusions with etoposide had shorter
survival.
Subsequent patency was determined for 39 sites. Of 34
which ended without failure, 28 were patent while six were
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Table I Effect of sex, age, rate and site on infusion survival
Relative
Total Number rate of
Factor number failing failure x2
Sex
Female
Male
Side
Right
Left
Sitea
Hand
WriStb
Forearm
Cubital fossa
Age (years)
<46
45-60
>60
Rate (ml h-')
<80
80-125
> 125
168 45 1.16
116 33 0.84
128 39 1.21
156 36 0.81
33
62
175
12
65
120
99
22
94
168
7
15
50
3
24
28
26
10
27
41
0.57
0.91
1.16
0.87
1.49
0.88
0.87
0.89
1.06
0.99
Datacomprise infusions intended to last forlonger than 24 hgiven to
oncology patients and were anlaysed by univariate survival analysis.
aTwo other sites in leg veins did not fail. bSited such that wrist
movements might affect the cannula. n.s., not significant.
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Figure I Univariate survival curves for infusions in oncology
patients. The thicker line represents infusions delivering
chemotherapy.
Table II Effects ofchemotherapeuticdrugs on survival ofintravenous
infusions
Numberfailing Cytoxic All Infusions
/Total number Failure Failure
Drug (%failed) rate ratio X2 rate ratio X2
Bleomycin 12/56 (25%) 1.11 0.11 1.01 0.01
Cisplatin 32/159 (21%) 0.48 6.69* 0.66 3.36
Cyclophosphamide 0/4 (0%) - 0.22 - 0.31
Doxorubicin 2/9 (12%) 2.82 2.27 2.29 1.41
Etoposide 17/56 (30%) 1.49 1.85 1.36 1.27
Ifosphamide 4/14 (30%) 1.03 0.01 1.10 0.03
Methotrexate 15/62 (25%) 1.59 2.34 1.38 1.29
Treosulphan 1/16 (7%) 0.28 1.82 0.27 1.94
Vincristine 0/4 (0%) - 0.66 - 0.73
5-Fluorouracil 5/21 (20%) 0.50 2.29 0.56 1.59
*P<0.05; all others not significant.
Table III Statistics for factors selected by multifactorial analysis
X2for removal at Hazard ratio
Step Factor the last step P (95% confidence limits)
I Plus cisplatin 10.20 0.0014 0.452 (0.264-0.776)
2 Plus 7.46 0.0063 2.467 (1.285-4.735)
etoposide
3 Sex (male) 5.74 0.0166 0.553(0.335-0.911)
not (veins in two were replaced by cords and in four had
disappeared). In contrast, at only one of the five sites classed
as failed was the vein patent while in three it had been
replaced by a palpable cord and in one it had disappeared.
This association between proportions of infusions ending in
failure and subsequent loss of patency was highly significant
(X2= 11.04; P>0.001).
Discussion
Infusions which extravasated or became phlebitic were deem-
ed to have failed. Except for extravasation which occurs
shortly after an infusion has started because the cannula tip
was not in the vein, extravasation is likely to have a similar
aetiology to phlebitis with both being induced by irritation to
the endothelium by the infusate (Hecker et al., 1984; Hecker,
1989). This irritation probably causes venoconstriction
which, prior to the development of clinical phlebitis, slows
and makes the drip rate irregular (Hecker & Lewis, 1984).
Alternatively venoconstriction may stop flow through the
vein, leading to leakage (extravasation) through the hole
made where the cannula was inserted into the vein (Hecker et
al., 1984).
The distinction between phlebitis and extravasation at
times is unclear as swelling at the time of cannula removal
indicates extravasation but this disappears after a few hours
making the phlebitic signs of tenderness and vein cording
more apparent. In a separate survey comparing extravasation
with phlebitis, there was no significant difference in the life
tables for failure due to phlebitis and due to extravasation
(Hecker, 1989).
The multivariate analysis selected only two drugs with
altering failure, etoposide with increased failure and cisplatin
with decreased failure. The finding for cisplatin is likely to be
an artifact for the following reason. Survival analysis is
intended for continuous exposure to a risk factor and
appears to be the best method for these infusion data. Only
one drug (5-FU) was normally given continuously while
several others (e.g. etoposide) were given either intermittently
during infusions (approximately continuous delivery) or else
given as bolus injections at the start. Once a vein has been
exposed to a drug, the risk of failure resulting from any local
irritation from the drug should be increased for many hours
and so potentially could be detected with survival analysis.
However, two drugs, bleomycin and cisplatin, which were
administered by short infusions were usually not given until
several hours after infusions had commenced. The pre-hydra-
tion period for cisplatin was typcially 24 h and infusions that
failed before it had been given were not classed as cisplatin
infusions as the drug could not have affected the vein. This
resulted in decreasing the RRF for cisplatin (equivalent to
shifting its survival curve to the right). There was a similar
but smaller effect for bleomycin as pre-hydration was nor-
mally only for 6 h. There is no simple solution to this prob-
lem (Anderson et al., 1980) but, as it is improbable that
cisplatin would decrease infusion failure, then the likelihood
is that it had no effect.
Henney et al. (1977) reported briefly that 27 of 82 agents
investigated by the Cancer Therapy Evaluation Program of
the National Cancer Institute were implicated with frequent
incidences of thrombophlebitis. The only relevant detail given
was that no drug was given by 'prolonged intravenous infu-
sion'. Of the drugs studied here, only doxorubicin was in their
group classed as 'frequent incidence' while bleomycin, vin-
cristine and 5-FU were in the 'frequent' group. The failure
rate ratio for doxorubicin was high (Table II) and it might be
that the number of infusions with this drug was too small for
more than a large significant difference to be detected. Alter-
natively it may be that it does not irritate the vein during
transient passage along it but only causes problems only after
extravasating.
Almost one-quarter of these cytoxic infusions failed. This
may have been a slight under-estimation as five patients later
reported that phlebitic-like signs developed after they had left662 J.F. HECKER
hospital. To put this 23% failure rate in perspective, the
survival curve for cytotoxic infusions was similar to that for
non-cytoxic infusions given to oncology patients and signifi-
cantly better (x2 = 7.69, P>0.01; failure ratio = 0.66) than
for 357 infusions in non-oncology patients in the hospital
(Hecker, in preparation). Band and Maki (1980) reported a
phlebitis rate of 36.1% for oncology patients.
These data show that it is unlikely that the drugs given
frequently, bleomycin, cisplatin and methotrexate, are
irritant. Fewer infusions involved the other drugs and so only
extreme irritancy would be detecting.
The lack of evidence for irritancy for drugs other than
etoposide suggests that failure was caused by other factors
which were common to both the cytoxic and non-cytoxic
infusions. Similar surveys of intravenous antibiotics and
other drugs have identified relatively few drugs that increase
infusion failure (Hecker, 1989; Hecker et al., unpublished
data). However, acidity of the dextrose and saline crystaloid
solutions (typically pH 4.5 and 5.5 respectively (Lebowitz et
al., 1971; Mostert, 1971; Tse, 1971)) is probably important.
These solutions are given in large volumes, are mildly irritant
to veins, and have often been implicated in the failure of
intravenous infusions as neutralisation decreases the
incidence of failure (Eremin & Marshall, 1977; Flores-Vega
et al., 1970; Fonkalsrud et al., 1968).
The multivariate analysis suggested that failure was signi-
ficantly more rapid in women. I have done three surveys of
non-oncology patients using similar methods and sex was
identified as one of the few significant factors (failure more
rapid in women) in two (unpublished) but not in the third
(Hecker, 1989). The reason for a possible sex effect is un-
known.
Problems with venous access were apparent in many of
these patients and three required either use of foot veins or a
central venous line for therapy to continue. Cannulation of
hand and arm veins was often difficult in many other patients
and it appeared that previous therapy had resulted in the loss
of many superficial veins. Follow-up was possible only for a
proportion of patients but it showed that the occurrence of
phlebitis and/or extravasation usually resulted in vein loss,
sometimes with the formation of a hard palpable cord.
Observations have led me to the conclusion that progres-
sive vein loss due to repeated intravenous therapy is also a
problem in other than oncology patients. However, it has
received no attention in the medical literature. Techniques
which reduce the incidence of infusion failure, such as local
transcutaneous glyceryl trinitrate (Wright et al., 1985;
Khawaja et al., 1988) or the addition of small amounts of
heparin to solutions (Tanner et al., 1980; DeCock et al.,
1984; Alpan et al., 1984) could be considered to conserve
veins of oncology patients who are likely to require repeated
intravenous therapy.
There is no recognised method for identifying drugs which
have deleterious effects on veins and it is difficult to find the
origins of statements in promotional and other literature that
particular drugs 'may cause phlebitis'. I suggest that new
intravenous chemotherapeutic drugs should be tested by
methods similar to these (i.e. compared with similar infusions
without the drug) to identify any that are irritant.
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